Oculis Holding AG (OCS) Stock Price & Analysis
Oculis Holding AG (OCS) closed at USD 7.4 on Thursday, October 15, 2026, up 3.21% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 7.17; the Oct 15, 2026 session ranged USD 7.15–7.6 on volume of 559,160 shares. Market capitalization is $455.75M, with a 52-week range of USD 7.11–34.48 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/OCS.md
Key facts (OCS)
- Analysts: Buy (mean 1.70 on a 1–5 scale) (10 analysts), mean target USD 36.84 (range 19.65–43.94).
- Total return with dividends: 1Y -65.7% vs S&P 500 +18.1%; 5Y -24.6% vs S&P 500 +85.1%.
- Next earnings: 2026-11-03, EPS estimate USD -0.4, revenue estimate $158K.
Analysts (OCS)
Consensus Buy (mean 1.70 on a 1–5 scale), 10 analysts; mean target USD 36.84 (low 19.65, high 43.94).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-18 | HC Wainwright & Co. | Target raised | Buy | $26 → $39 |
| 2026-08-14 | JP Morgan | Target lowered | Overweight | $23 → $20 |
| 2026-08-05 | HC Wainwright & Co. | Maintained | Buy | $26 |
Total return (dividends reinvested) (OCS)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -65.7% | -24.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -65.8% | -5.5% |
| Volatility (annualized) | 73.3% | 54.6% |
| Max drawdown | -78.0% (May 2026→Oct 2026) | -77.3% (May 2026→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 7.4 |
|---|---|
| Change | ▲ 3.21% (up) |
| Previous Close | USD 7.17 |
| Open | USD 7.25 |
| Day Range | USD 7.15 – 7.6 |
| 52-Week Range | USD 7.11 – 34.48 |
| Volume | 559,160 shares |
| Market Cap | $455.75M |
| Exchange | NGM |
Technical Analysis (OCS)
Nexqual's technical model rates OCS "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 22.08 (oversold) |
| vs SMA50 | Below (USD 10.87) |
| MACD | -0.94 (negative) |
Analyst Ratings (OCS)
Wall Street analysts rate OCS "Buy" based on 10 analysts, with a mean price target of USD 36.84 (range USD 19.65–43.94), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 36.84 |
| High Target | USD 43.94 |
| Low Target | USD 19.65 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (OCS)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD -0.4 |
| Revenue Estimate | $157,590 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.16 vs est -0.38 ▲ beat |
| 2026-03-31 | USD -0.49 vs est -0.41 ▼ miss |
| 2025-12-31 | USD -0.42 vs est -0.41 ▼ miss |
| 2025-09-30 | USD -0.32 vs est -0.41 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (OCS)
| Total Revenue | $1.17M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +18.80% |
| Gross Margin | +0.00% |
| Operating Margin | -7602.58% |
| Profit Margin | +0.00% |
| ROE | -43.70% |
| Debt / Equity | 0.01 |
| Current Ratio | 8.35 |
| Total Cash | $228.32M |
| Total Debt | $2.54M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (OCS)
Nexqual rates Oculis Holding AG's overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Strong — Revenue +75% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — CHF 228M cash vs CHF 3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -CHF 66M (TTM) |
| Efficiency | Critical — ROE -44%, ROA -25.0% |
Ownership (OCS)
| Insider Ownership | +3.53% |
|---|---|
| Institutional Ownership | +47.22% |
| Shares Outstanding | 61.59M |
| Float | 52.39M |
| Short % of Float | +3.31% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (OCS)
Oculis Holding AG is led by Riad Sherif (age 57), CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| CEO & Director | Riad Sherif (age 57) |
|---|---|
| Chief Financial Officer | Sylvia Cheung (age 50) |
| Chief Technology Officer | Gudrun Bachmann |
| Chief Scientific Officer | Ramin Tadayoni |
| President of Research & Development | Snehal Shah Pharm.D. |
Major Backers & Investors (OCS)
Notable institutional backers of Oculis Holding AG include Eqt Fund Management S.a R.l., Gildi - Lifeyrissjodur, Aberdeen Group plc, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Eqt Fund Management S.a R.l. | 11.99% |
| Gildi - Lifeyrissjodur | 4.19% |
| Aberdeen Group plc | 3.72% |
| Millennium Management | 3.52% |
| Pivotal bioVenture Partners Investment Advisor, LLC | 2.6% |
| abrdn Healthcare Investors | 2.52% |
| Citadel | 1.7% |
| Braidwell LP | 1.44% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt